← Leaderboards
Ronald N. Harty
University Of Pennsylvania
$14,036,721
Attributed
$14,036,721
Total exposure
20
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,036,721 · 20
By mechanism
R21$6,707,258 · 14
R42$3,045,306 · 1
R41$1,496,363 · 3
R33$1,407,437 · 1
R01$1,380,357 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Susan R Ross$18,891,931
- Tzipora Sarah Karin Eisinger$2,119,857
- Robert W. Doms$20,416,408
- Sara Cherry$26,280,643
- Francisco A Gonzalez-Scarano$10,891,253
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsEbola VirusMediatingVirusViralAntiviral AgentsFilovirusVirus DiseasesInfectionBasePathogenLeadCellsPreventLaboratoriesRna VirusesVirus-Like ParticleVirus Host InteractionFutureCategoriesBioterrorismVirionUbiquitin-Protein LigaseIn Vitro
Grant awards (43)
The Extracellular Matrix as a Determinant of Filovirus Infectivity.$480,249
R21 · FY2025 · AI · contact PI
Nuclear Localization and Function of the Ebola Virus VP40 Protein$446,875
R21 · FY2025 · AI · contact PI
Role of Host Filamin Proteins in Regulating Filovirus Entry and Egress$212,000
R21 · FY2024 · AI · contact PI
Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses$1,012,857
R42 · FY2023 · AI · contact PI
Development of Host- Oriented Therapeutics Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),$292,428
R41 · FY2023 · AI · contact PI
Role of Host Filamin Proteins in Regulating Filovirus Entry and Egress$268,250
R21 · FY2023 · AI · contact PI
Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses$1,015,449
R42 · FY2022 · AI · contact PI
Development of Host- Oriented Therapeutics Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),$306,500
R41 · FY2022 · AI · contact PI
Role of Host Angiomotin as a Central Regulator of Filovirus Egress and Dissemination$225,313
R21 · FY2022 · AI · contact PI
Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses$1,017,000
R42 · FY2021 · AI · contact PI
Role of Host Angiomotin as a Central Regulator of Filovirus Egress and Dissemination$285,833
R21 · FY2021 · AI · contact PI
Predicted Role of Ebola VP40-Host Interactions in Ocular Pathology and Persistence$196,879
R21 · FY2021 · EY · contact PI
Predicted Role of Ebola VP40-Host Interactions in Ocular Pathology and Persistence$243,000
R21 · FY2020 · EY · contact PI
Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses$297,435
R41 · FY2019 · AI · contact PI
Dueling PPxY Motifs of Filovirus VP40 and Host Angiomotin: Effects on Innate Immune Defenses and Tight Junction Integrity at Immune Privileged Sites$203,250
R21 · FY2019 · AI · contact PI
Modular Domains of Host Proteins Regulate Filovirus Maturation$201,250
R21 · FY2019 · AI · contact PI
Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses$300,000
R41 · FY2018 · AI · contact PI
Dueling PPxY Motifs of Filovirus VP40 and Host Angiomotin: Effects on Innate Immune Defenses and Tight Junction Integrity at Immune Privileged Sites$258,750
R21 · FY2018 · AI · contact PI
Modular Domains of Host Proteins Regulate Filovirus Maturation$246,400
R21 · FY2018 · AI · contact PI
Host-Oriented Therapeutics Targeting Filovirus Budding.$472,800
R33 · FY2016 · AI · contact PI
Host-Oriented Therapeutics Targeting Filovirus Budding.$467,998
R33 · FY2015 · AI · contact PI
DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS AGAINST RNA VIRUSES$300,000
R41 · FY2015 · AI · contact PI
Innate Immune Regulation of Intracellular Pathways Involved in Filovirus Budding$200,000
R21 · FY2015 · AI · contact PI
Host-Oriented Therapeutics Targeting Filovirus Budding.$466,639
R33 · FY2014 · AI · contact PI
Innate Immune Regulation of Intracellular Pathways Involved in Filovirus Budding$240,000
R21 · FY2014 · AI · contact PI
Host-Oriented Therapeutics Targeting Filovirus Budding.$222,664
R21 · FY2013 · AI · contact PI
Host-Oriented Therapeutics Targeting Filovirus Budding.$200,000
R21 · FY2012 · AI · contact PI
Innate Immune Defenses Against Filoviruses.$237,600
R21 · FY2011 · AI · contact PI
Innate Immune Defenses Against Filoviruses.$199,896
R21 · FY2010 · AI · contact PI
Role of ISG15 in Inhibition of Ebola Virus Budding$185,133
R21 · FY2009 · AI · contact PI
Packaging of Ebola Virus RNA into Budding VLPs$193,134
R21 · FY2008 · AI · contact PI
Role of ISG15 in Inhibition of Ebola Virus Budding$193,134
R21 · FY2008 · AI · contact PI
Role of ISG15 in Inhibition of Ebola Virus Budding$236,250
R21 · FY2007 · AI · contact PI
Packaging of Ebola Virus RNA into Budding VLPs$235,938
R21 · FY2007 · AI · contact PI
Budding of Negative-sense RNA Viruses$270,857
R01 · FY2006 · AI · contact PI
Ebola Virus VP40-Host Interactions In VIvo$317,000
R21 · FY2005 · AI
Budding of Negative-sense RNA Viruses$277,375
R01 · FY2005 · AI
Ebola Virus VP40-Host Interactions In VIvo$302,960
R21 · FY2004 · AI
Budding of Negative-sense RNA Viruses$277,375
R01 · FY2004 · AI
Budding of Negative-sense RNA Viruses$277,375
R01 · FY2003 · AI
Analysis of the Ebola Virus VP24 Channel Protein$237,750
R21 · FY2003 · AI
Budding of Negative-sense RNA Viruses$277,375
R01 · FY2002 · AI
Analysis of the Ebola Virus VP24 Channel Protein$237,750
R21 · FY2002 · AI